Vericel Corporation (VCEL) PT Raised to $20 at BTIG
BTIG analyst Ryan Zimmerman raised the price target on Vericel Corporation (NASDAQ: VCEL) to $20.00 (from $17.00) while maintaining a Buy rating following strong results driven by both MACI and Epicel growth.
Zimmerman said the guidance raise was 'encouraging' as both biopsy growth and expanding surgeon usage are driving adoption beyond early adoption, in their view.